ArticleJournal of the American Heart Association2026
Cardiovascular Risk Management in Adults With Diagnosed Diabetes in Mexico From 2016 to 2023: A Retrospective Analysis of Nationally Representative Surveys.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a prospective, observational, population-based analysis of adults with diabetes in Mexico City.Lancet regional health. Americas · 2026Article
- Early assessment of diabetes care target attainment in Mexico's federalized public health system: alignment with Global Diabetes Compact 2030.Frontiers in clinical diabetes and healthcare · 2026Article
- When Risk is Unequal: Gendered Pathways to Cardiovascular Disease.Global heart · 2026Article
- Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes in 24,943 adults in Mexico City.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective cardiovascular disease (CVD) risk management is essential for optimal diabetes care. Here, we estimated the prevalence and determinants of CVD risk factor control among individuals with diagnosed diabetes in Mexico.
methodsWe analyzed data from individuals ≥20 years with diagnosed diabetes from 2016 to 2023 Mexican National Health and Nutrition Surveys. We estimated the prevalence of glycemic, blood pressure, noncurrent smoking, low-density lipoprotein cholesterol, and combined CVD risk factor control. We estimated use of blood pressure-lowering, cholesterol-lowering, and glucose-lowering medication and explored determinants of control achievement using logistic regression.
resultsWe analyzed data from 2916 participants, representing 43.2 million adults with diagnosed diabetes during 2016 to 2023. In 2023, glycemic control was 29% (95% CI, 21%-38%), blood pressure control 22.9% (95% CI, 14%-31%), and noncurrent smoking 89% (95% CI, 81%-96%). The prevalence of high or very-high CVD risk using Systematic Coronary Risk Evaluation 2-Diabetes increased from 59.8% (95% CI, 52.1%-67.0%) in 2016 to 68.4% (95% CI, 55.6%-78.9%) in 2023, representing ~5.1 million adults. Low-density lipoprotein cholesterol control increased from 2.8% (95% CI, 1.2%-4.4%) in 2016 to 6.6% (95% CI, 1.9%-11.2%) in 2023 and statin use from 5.5% in 2016 to 63% in 2023. Combined risk factor control achievement was low due to suboptimal low-density lipoprotein cholesterol control and was more likely achieved in women, younger individuals, and those with college education or living in states with higher socioeconomic position.
conclusionsDespite increasing CVD risk during this period, glycemic and CVD risk factor management for adults with diabetes in Mexico remains suboptimal. Our findings suggest a need for strategies to improve CVD risk management to reduce diabetes-related mortality and complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.